An industry-first FDA approval for a nonalcoholic steatohepatitis (NASH) therapy may still be a ways off. After reviewing Intercept Pharmaceuticals’ latest applic...

News of the Federal Trade Commission (FTC) lawsuit challenging Amgen’s $28 billion buyout of Horizon prompted an immediate question: Will the U.S. antitrust enforcer...

After a high-profile rejection for Innovent Biologics’ Tyvyt, another China-made PD-1 inhibitor is starting a bid to win an FDA approval. Elevar Therapeutics has ...

AbbVie's aesthetics unit is growing its product catalog once again with a new FDA approval. The product, called Skinvive, nabbed an FDA nod this we...

DeepIntent and Roku want to challenge the idea that watching TV on streaming services is the preserve of the young. With 79% of people aged 50 and up using the servi...

The European Laboratory Research & Innovation Group (ELRIG) UK today announced the appointment of Nick Clare to the ELRIG board. He will chair and lead the Vendo...

The costs for Roche to decommission and demolish its former API manufacturing plant in County Clare, Ireland, continue to climb, with the bill now reaching €57.3 mil...

Novartis’ star drug Cosentyx recently hit a sales slump thanks to tough competition from newer biologics. But for the company’s next phase of growth in immunology, t...

The jury has spoken, giving a unanimous "yes" to push Perrigo’s birth control tablet Opill over the counter. Wednesday, experts from a joint FDA meeting of outsid...

After a little over four months as Teva's CEO, Richard Francis is getting ready to debut his long-term vision for the drugmaker. In Francis' first quarter as Teva...